

## Therapeutics for Women's Health: Technologies and Global Markets

Market Research Report | 2025-03-25 | 159 pages | BCC Research

#### **AVAILABLE LICENSES:**

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

#### Report description:

Description

#### Report Scope

This report provides a detailed analysis of the global therapeutics for women's health technologies market, including coverage of market drivers, restraints and opportunities. It also includes analyses of this market's competitive environment and products. The report presents market estimates and forecasts for women's health therapeutics and provides market projections through 2029. For this analysis, the market is segmented by conditions related to women's health, including breast cancer, postmenopausal osteoporosis, menopause, endometriosis and polycystic ovary syndrome (PCOS), and by geographic region. The report provides company profiles of the market's leading players that feature detailed information about each company's business segments, financials, product portfolios and recent developments.

By region, the global therapeutics for women's health technologies market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes the U.K., Germany, Spain, France, Italy and the Rest of Europe; Asia-Pacific comprises China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. The rest of the World includes the Middle East and Africa, and South America. In the report's market estimates, 2021 and 2022 serve as historical years, 2023 as the base year, and data forecasts are given through 2029. Report Includes

- 46 data tables and 63 additional tables
- An overview of the global market and technologies for women's health therapeutics
- Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Study of women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS), including their historical background, stages, symptoms, risk factors -and genetic factors, diagnosis, and treatment options
- Discussion on aging and women's health disorders, women and sexual health such as female sexual arousal disorder, female

orgasmic disorder and vaginismus, as well as the relationship between infertility and cancer

- Information about significant products, companies, issues and trends affecting the women's disorders and diseases industry
- Evaluation of the impact of demographic, economic and other factors that will drive demand in the market for women's health therapeutics
- Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of the market drivers, restraints and other forces impacting the global market, as well as an evaluation of current and projected market size
- A discussion of ESG challenges and practices in the industry
- Market share analysis of the key companies and coverage of their proprietary technologies, strategic alliances, and other market strategies
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Pfizer Inc., Eli Lilly and Company, Novartis AG and Amgen Inc.

**Executive Summary** 

#### Summary:

The global therapeutics for women's health technologies market is expected to grow from \$61.5 billion in 2024 and is projected to reach \$81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.

In 2023, the global therapeutics for women's health technologies market was valued at \$58.3 billion. The market is forecast to grow at a CAGR of 5.7% to reach \$81.2 billion by the end of 2029.

The factors driving market growth are the growing population of older women and the rising awareness of and accessibility to healthcare and advanced therapeutic products. High treatment costs and regulatory challenges are restraining the market's growth.

In 2023, the breast cancer segment of the global therapeutics for women's health technologies held the largest share, 55.1% of the market segmented by women's health disorders, and this segment is expected to grow at a CAGR of 5.9% during the forecast period.

#### **Table of Contents:**

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Insights
Chapter 2 Market Overview
Overview

**Definitions** 

**Breast Cancer** 

Postmenopausal Osteoporosis

Menopause

Endometriosis

Polycystic Ovary Syndrome (PCOS)

Scotts International. EU Vat number: PL 6772247784

**Historical Context** 

Aging and Women's Health Disorders

Chapter 3 Market Dynamics

Overview

**Market Drivers** 

Rising Population of Older Women

Increasing Awareness and Accessibility

**Market Restraints** 

**High Treatment Costs** 

**Regulatory Challenges** 

Market Opportunities

Advances in Personalized Medicine

**Emerging Markets** 

Chapter 4 Emerging Technologies

Overview

Digital Health Solutions

Advanced Fertility Technologies

Targeted Biologics and Biosimilars

Nanotechnology-Driven Drug Delivery

Gene Therapy and CRISPR

Chapter 5 Pipeline Assessment and Analysis

Overview

Women's Health Therapeutics: Key Clinical Trial Developments

Drugs in Pipeline

Overview of Osteoporosis Drug Development Pipeline

Chapter 6 Regulatory Structure

Overview of Regulations

U.S.

**Drug Development and Approval Process** 

Types of Applications Reviewed by FDA

Canada

Food and Drugs Act (F-27)

Europe

Japan

Chapter 7 Market Segmentation Analysis

Segmentation Breakdown

Market Analysis, by Women's Health Disorder

**Breast Cancer** 

Postmenopausal Osteoporosis

Menopause

Endometriosis

**PCOS** 

Geographic Breakdown

Market Analysis, by Region

North America

Europe

Asia-Pacific

Scotts International, EU Vat number: PL 6772247784

Rest of the World

Chapter 8 Competitive Landscape

Overview

Market Players and Strategies

Patent Analysis

**Key Developments** 

Chapter 9 ESG Perspective

Introduction to ESG

ESG Goals for the Pharmaceutical Sector

Focus on Energy Efficiency

Reduce Emissions and Carbon Footprint

Waste Generation and Disposal

Manufacturing, Distribution and Transportation

Social Responsibility

Governance

ESG Risk Ratings in the Pharmaceutical Industry

Concluding Remarks from BCC Research

Chapter 10 Appendix

Methodology

Sources

**Abbreviations** 

**Company Profiles** 

ABBVIE INC.

AMGEN INC.

ASAHI KASEI CORP.

**ASTRAZENECA** 

**BAYER AG** 

BRISTOL-MYERS SQUIBB CO.

EISAI CO. LTD.

F. HOFFMANN-LA ROCHE LTD.

JOHNSON & JOHNSON SERVICES INC.

LILLY

MERCK & CO. INC.

**NOVARTIS AG** 

**NOVO NORDISK A/S** 

PFIZER INC.

TEVA PHARMACEUTICAL INDUSTRIES LTD.



To place an Order with Scotts International:

# Therapeutics for Women's Health: Technologies and Global Markets

Market Research Report | 2025-03-25 | 159 pages | BCC Research

<ul><li>Print this form</li></ul>				
<ul><li>Complete the rel</li></ul>	evant blank fields and sign			
<ul><li>Send as a scanne</li></ul>	ed email to support@scotts-interna	tional.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$4650.00
	2-5 Users License			\$5580.00
	\$6696.00			
	\$8035.00			
			VAT	
			Total	
*Please sircle the releva	nt license option. For any questions ple	asa santast sunnart@s	cotts international com or 0049 602 2	04 246
	23% for Polish based companies, indivi			
U VAI WIII be duded de	25% for Folish based companies, marv	iddais and Lo based col	impunies who are unable to provide a	valia EO vac ivaliiber:
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / NIP number*		
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-12	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

### Scotts International. EU Vat number: PL 6772247784